Auranofin
Structural formula | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | |||||||||||||||||||
Non-proprietary name | Auranofin | ||||||||||||||||||
other names |
(2,3,4,6- Tetra- O -acetyl-1-thio-β- D -glucopyranosato) (triethylphosphine) gold ( IUPAC ) |
||||||||||||||||||
Molecular formula | C 20 H 34 AuO 9 PS | ||||||||||||||||||
External identifiers / databases | |||||||||||||||||||
|
|||||||||||||||||||
Drug information | |||||||||||||||||||
ATC code | |||||||||||||||||||
Drug class |
Gold preparation |
||||||||||||||||||
properties | |||||||||||||||||||
Molar mass | 679.49 g mol −1 | ||||||||||||||||||
Physical state |
firmly |
||||||||||||||||||
Melting point |
110-111 ° C |
||||||||||||||||||
safety instructions | |||||||||||||||||||
|
|||||||||||||||||||
Toxicological data | |||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Auranofin (trade name: Ridaura ) is an organic gold compound that is used as a medicinal substance in the basic therapy of chronic, progressive polyarthritis . Today it is only used in exceptional cases when other basic therapeutic agents such as methotrexate fail .
The mechanism of action of the substance is not known, but it is suspected that auranofin is attached to cysteine residues in the catalytic center of proinflammatory transcription factors e.g. B. of AP-1 and NF-κ-B binds and thus prevents their binding to their DNA consensus sequences . This reduces the expression of inflammatory mediators. There is also discussion about whether the gold will react with the SH groups.
Auranofin can be used orally (in tablet form) and was first approved in 1982. The finished medicinal product is available in many EU countries.
Individual evidence
- ↑ a b Entry on Auranofin. In: Römpp Online . Georg Thieme Verlag, accessed on November 10, 2014.
- ↑ a b Auranofin data sheet from Sigma-Aldrich , accessed on July 15, 2018 ( PDF ).
- ↑ WHO Drug Information (PDF; 5.7 MB), Vol. 2, No. 1 (1988), p. 7.